The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

CHRONOS: Anti-EGFR rechallenge therapy with panitumumab driven by ctDNA molecula...

Prof Andrea Sartore-Bianchi - Ospedale Niguarda, Milan, Italy

CHRONOS: Anti-EGFR rechallenge therapy with panitumumab driven by ctDNA molecular selection in mCC ( Prof Andrea Sartore-Bianchi - Ospedale Niguarda, Milan, Italy )

Adjuvant chemo following chemoradiation as treatment for locally advanced cervic...

Dr Linda Mileshkin - Peter MacCallum Cancer Center, Melbourne, Australia

Adjuvant chemo following chemoradiation as treatment for locally advanced cervical cancer compared to chemoradiation alone ( Dr Linda Mileshkin - Peter MacCallum Cancer Center, Melbourne, Australia )

Tislelizumab in oesophageal cancer after systemic therapy

Dr Jaffer Ajani - The University of Texas MD Anderson Cancer Center, Texas, USA

Tislelizumab in oesophageal cancer after systemic therapy ( Dr Jaffer Ajani - The University of Texas MD Anderson Cancer Center, Texas, USA )

HCRN GU 16-257: Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with sel...

Dr Matthew Galsky - Icahn School of Medicine at Mount Sinai, New York, USA

HCRN GU 16-257: Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in MIBC patients ( Dr Matthew Galsky - Icahn School of Medicine at Mount Sinai, New York, USA )

CodeBreaK100: Sotorasib in pretreated KRAS p.G12C mNSCLC

Dr Ferdinandos Skoulidis - MD Anderson Cancer Center, Houston, USA

CodeBreaK100: Sotorasib in pretreated KRAS p.G12C mNSCLC ( Dr Ferdinandos Skoulidis - MD Anderson Cancer Center, Houston, USA )

PEACE-1: Abiraterone acetate plus prednisone and/or local radiotherapy in men wi...

Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France

PEACE-1: Abiraterone acetate plus prednisone and/or local radiotherapy in men with de novo mCSPC ( Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France )

CheckMate067 outcomes: Nivolumab plus ipilimumab in advanced melanoma

Dr Jedd Wolchok - Memorial Sloan Kettering Center, New York, USA

CheckMate067 outcomes: Nivolumab plus ipilimumab in advanced melanoma ( Dr Jedd Wolchok - Memorial Sloan Kettering Center, New York, USA )

Can multiple endpoints in MM clinical papers create new insights?

Prof Evangelos Terpos and Prof Nina Shah

Can multiple endpoints in MM clinical papers create new insights? ( Prof Evangelos Terpos and Prof Nina Shah )

LEAP-004: Lenvatinib + pembrolizumab for patients with advanced melanoma and con...

Dr Ana Arance - Hospital Clínic de Barcelona, Barcelona, Spain

LEAP-004: Lenvatinib + pembrolizumab for patients with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor ( Dr Ana Arance - Hospital Clínic de Barcelona, Barcelona, Spain )

Highlights from ASCO 2021

Dr Bishal Gyawali - Queen's University, Kingston, Canada

Highlights from ASCO 2021 ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

OncoAlert and ecancer ASCO roundup - Day 3

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer ASCO roundup - Day 3 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

PANAMA: Maintenance 5FU/LV plus panitumumab or 5FU/LV alone in RAS wildtype mCRC

Prof Dominik Modest - Charité Universitätsmedizin Berlin, Berlin, Germany

PANAMA: Maintenance 5FU/LV plus panitumumab or 5FU/LV alone in RAS wildtype mCRC ( Prof Dominik Modest - Charité Universitätsmedizin Berlin, Berlin, Germany )

More from ecancer